外周T细胞淋巴瘤(Peripheral T-cell lymphoma,PTCL)是一种生物学行为和临床表现呈现高度异质性和侵袭性的血液肿瘤,亚型种类繁多,不同亚型具有不同的临床特征、遗传学改变及治疗反应。因此,临床医师对其诊断和治疗常常面临较大困难。相对于常见的淋巴瘤...
CD30阳性皮肤T细胞淋巴瘤(CD30 positive cutaneous T cell lymphoma) 又称原发性CD30阳性皮肤T细胞淋巴瘤,为单发性或局限性皮肤损害,倾向溃疡(50%)和自然消退(25%)。罕见于儿童,男性多于女性。 审编医生 王帅
CD30在一小部分活化的T淋巴细胞和B淋巴细胞以及各种淋巴样肿瘤上表达,经典型霍奇金淋巴瘤(classical Hodgkin's lymphoma,cHL)和间变性大细胞淋巴瘤(anaplastic large-cell lymphoma,ALCL)近乎100%的肿瘤细胞表达CD30,因此CD30成为cHL和ALCL诊断的常规标志物,此...
CD30阳性皮肤T细胞淋巴瘤概述 CD30阳性皮肤T细胞淋巴瘤(CD30positivecutaneousTcelllymphoma)又称原发性CD30阳性皮肤T细胞淋巴瘤,为单发性或局限性皮肤损害,倾向溃疡(50%)和自然消退(25%)。罕见于儿童,男性多于女性。
1.非MF-CD30阴性皮肤大T细胞淋巴瘤(negativecutaneouslargeT-celllymphoma)呈单发性或泛发性斑块、结节或肿瘤。无斑片期可与MF区别。预后差,5年存活率为15%。有些以往称为dembleeMF的病例可归类于本组肿瘤。皮肤外受累可在皮肤受累之前或与皮肤受累几乎同时发生。
一项来自美国的报道,其通过对纳入的340例外周T细胞淋巴瘤非特指型(Peripheral T Cell Lymphoma, Not Otherwise Specified, PTCL-NOS)患者临床、病理指标进行单因素分析得出CD30表达是预后不佳的危险因素[2]。此外,另有报告指出具有强表达CD30(cutoff≥80%)PTCL-NOS患者的存活率极差,5年OS与PFS分别为19%和9%[3]...
[4] NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphomas (Version 1.2020)[5] 中国临床肿瘤学会（CSCO）淋巴瘤诊疗指南（2019）[6] Pro, B., et al. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II ...
CD30-positive cutaneous T-celllymphoma w ith concurrent solid tumour. Au WY,Yeung CK,Chan HH,et al. B r J D ermatol . 2002Au WY,Yeung CK,Chan HH,et al.CD30-positive cutaneous T-celllymphoma w ith concurrent solid tumour.B r J D ermatol. 2002...
T-cell lymphomaCD30 antigenWe observed a 61-year-old woman, presenting with deeply infiltrating, erythemato-cyanotic, sometimes ulcerated or crusted plaques and nodules, mainly located on the lower limbs. Similar lesions had been present for more than 4 years, with a typical evolution: fast ...